Literature DB >> 2612557

Oesophageal injury associated with pivmecillinam tablets.

O Mortimer1, B E Wiholm.   

Abstract

Thirty-one cases of pivmecillinam-associated oesophagitis or ulceration verified at endoscopy have been reported in Sweden between 1978 and 1987. There were 29 women and two men of average age 30 years (range 15-77 years). Dysphagia and retrosternal pain often developed within the first days of treatment and resolved without complications within days of stopping treatment. Based on sales and prescription data, this complication appears to be rare, with 25-36 reported cases per million treatment courses. Further galenical development of the tablets and better patient information should reduce the number of patients injured.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2612557     DOI: 10.1007/bf00562553

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Drug-induced oesophageal injury.

Authors:  F J Collins; H R Matthews; S E Baker; J M Strakova
Journal:  Br Med J       Date:  1979-06-23

2.  The ulcerogenic effect on the oesophagus of three beta-adrenoceptor antagonists, investigated in a new porcine oesophagus test model.

Authors:  S G Olovson; J A Björkman; L Ek; N Havu
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1983-11

3.  Gastroscopic and pharmacokinetic evaluation of a new pivmecillinam tablet.

Authors:  H Hey; H J Frederiksen; J T Andersen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Drug-induced oesophageal ulceration.

Authors:  E C McCloy; S Kane
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-23

5.  Esophageal lesions caused by orally administered drugs. An experimental study in the cat.

Authors:  B Carlborg; O Densert
Journal:  Eur Surg Res       Date:  1980       Impact factor: 1.745

  5 in total
  1 in total

Review 1.  Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management.

Authors:  D Jaspersen
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.